• 10572 Citations
  • 39 h-Index
19972020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Filter
Article
2020

Impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice

Singh, A. P., Shum, E., Rajdev, L., Cheng, H., Goel, S., Perez-Soler, R. & Halmos, B., May 2020, In : Cancers. 12, 5, 1156.

Research output: Contribution to journalArticle

Open Access

Survival Disparities in Black Patients With EGFR-mutated Non–small-cell Lung Cancer

Cheng, H., Hosgood, H. D., Deng, L., Ye, K., Su, C., Sharma, J., Yang, Y., Halmos, B. & Perez-Soler, R., Mar 2020, In : Clinical lung cancer. 21, 2, p. 177-185 9 p.

Research output: Contribution to journalArticle

The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer

Alexander, M., Ko, B., Lambert, R., Gadgeel, S. & Halmos, B., Feb 1 2020, In : Expert Review of Respiratory Medicine. 14, 2, p. 137-147 11 p.

Research output: Contribution to journalArticle

2019
1 Scopus citations

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma

Sukrithan, V., Sandler, J., Gucalp, R., Gralla, R. & Halmos, B., May 2019, In : Clinical lung cancer. 20, 3, p. e242-e246

Research output: Contribution to journalArticle

2 Scopus citations

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Halmos, B., Tan, E. H., Soo, R. A., Cadranel, J., Lee, M. K., Foucher, P., Hsia, T. C., Hochmair, M., Griesinger, F., Hida, T., Kim, E., Melosky, B., Märten, A. & Carcereny, E., Jan 2019, In : Lung Cancer. 127, p. 103-111 9 p.

Research output: Contribution to journalArticle

13 Scopus citations
1 Scopus citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R. L., González Mendoza, R., Roy, A., Zhang, Y. & 188 others, Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D., Lerzo, G., Tatangelo, M., Varela, M., Zarba, J. J., Boyer, M., Gan, H., Gao, B., Hughes, B., Mallesara, G., Taylor, A., Burian, M., Barrios, C. H., de Castro Junior, D. O., Castro, G., Franke, F. A., Girotto, G., Lima, I. P. F., Nicolau, U. R., Pinto, G. D. J., Santos, L., Victorino, A. P., Chua, N., Couture, F., Gregg, R., Hansen, A., Hilton, J., McCarthy, J., Soulieres, D., Ascui, R., Gonzalez, P., Villanueva, L., Torregroza, M., Zambrano, A., Holeckova, P., Kral, Z., Melichar, B., Prausova, J., Vosmik, M., Andersen, M., Gyldenkerne, N., Jurgens, H., Putnik, K., Reinikainen, P., Gruenwald, V., Laban, S., Aravantinos, G., Boukovinas, I., Georgoulias, V., Kwong, D., Al-Farhat, Y., Csoszi, T., Erfan, J., Horvai, G., Landherr, L., Remenar, E., Ruzsa, A., Szota, J., Billan, S., Gluck, I., Gutfeld, O., Popovtzer, A., Benasso, M., Bui, S., Ferrari, V., Licitra, L., Nole, F., Fujii, T., Fujimoto, Y., Hanai, N., Hara, H., Matsumoto, K., Mitsugi, K., Monden, N., Nakayama, M., Okami, K., Oridate, N., Shiga, K., Shimizu, Y., Sugasawa, M., Takahashi, M., Takahashi, S., Tanaka, K., Ueda, T., Yamaguchi, H., Yamazaki, T., Yasumatsu, R., Yokota, T., Yoshizaki, T., Kudaba, I., Stara, Z., Cheah, S. K., Aguilar Ponce, J., Gonzalez Mendoza, R., Hernandez Hernandez, C., Medina Soto, F., Buter, J., Hoeben, A., Oosting, S., Suijkerbuijk, K., Bratland, A., Brydoey, M., Alvarez, R., Mas, L., Caguioa, P., Querol, J., Regala, E. E., Tamayo, M. B., Villegas, E. M., Kawecki, A., Karpenko, A., Klochikhin, A., Smolin, A., Zarubenkov, O., Goh, B. C., Cohen, G., du Toit, J., Jordaan, C., Landers, G., Ruff, P., Szpak, W., Tabane, N., Brana, I., Iglesias Docampo, L., Lavernia, J., Mesia, R., Abel, E., Muratidu, V., Nielsen, N., Cristina, V., Rothschild, S., Wang, H. M., Yang, M. H., Yeh, S. P., Yen, C. J., Soparattanapaisarn, N., Sriuranpong, V., Aksoy, S., Cicin, I., Ekenel, M., Harputluoglu, H., Ozyilkan, O., Harrington, K., Agarwala, S., Ali, H., Alter, R., Anderson, D., Bruce, J., Campbell, N., Conde, M., Deeken, J., Edenfield, W., Feldman, L., Gaughan, E., Goueli, B., Halmos, B., Hegde, U., Hunis, B., Jotte, R., Karnad, A., Khan, S., Laudi, N., Laux, D., Martincic, D., McCune, S., McGaughey, D., Misiukiewicz, K., Mulford, D., Nadler, E., Nunnink, J., Ohr, J., O'Malley, M., Patson, B., Paul, D., Popa, E., Powell, S., Redman, R., Rella, V., Rocha Lima, C., Sivapiragasam, A., Su, Y., Sukari, A., Wong, S., Yilmaz, E. & Yorio, J., Nov 23 2019, In : The Lancet. 394, 10212, p. 1915-1928 14 p.

Research output: Contribution to journalArticle

50 Scopus citations
2018
1 Scopus citations

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

KEYNOTE-407 Investigators, Nov 22 2018, In : The New England journal of medicine. 379, 21, p. 2040-2051 12 p.

Research output: Contribution to journalArticle

507 Scopus citations

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Gadgeel, S. M., Pennell, N. A., Fidler, M. J., Halmos, B., Bonomi, P., Stevenson, J., Schneider, B., Sukari, A., Ventimiglia, J., Chen, W., Galasso, C., Wozniak, A., Boerner, J. & Kalemkerian, G. P., Jan 1 2018, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

42 Scopus citations

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling

Wang, X., Li, G., Koul, S., Ohki, R., Maurer, M., Borczuk, A. & Halmos, B., May 18 2018, In : Oncotarget. 9, 38, p. 24914-24926 13 p.

Research output: Contribution to journalArticle

6 Scopus citations
1 Scopus citations

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study

Hochmair, M. J., Morabito, A., Hao, D., Yang, C. T., Soo, R. A., Yang, J. C. H., Gucalp, R., Halmos, B., Wang, L., Golembesky, A., Märten, A. & Cufer, T., Nov 2018, In : Future Oncology. 14, 27, p. 2861-2874 14 p.

Research output: Contribution to journalArticle

37 Scopus citations

Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1–negative human lung cancers

Cheng, H., Borczuk, A., Janakiram, M., Ren, X., Lin, J., Assal, A., Halmos, B., Perez-Soler, R. & Zang, X., Apr 15 2018, In : Clinical Cancer Research. 24, 8, p. 1954-1964 11 p.

Research output: Contribution to journalArticle

18 Scopus citations
8 Scopus citations

DNA polymerase ε deficiency leading to an ultramutator phenotype: A novel clinically relevant entity

Castellucci, E., He, T., Goldstein, D. Y., Halmos, B. & Chuy, J., May 2017, In : Oncologist. 22, 5, p. 497-502 6 p.

Research output: Contribution to journalArticle

10 Scopus citations

Emerging uses of biomarkers in lung cancer management

Halmos, B. & Levy, B., Sep 1 2017, In : Annals of Translational Medicine. 5, 18, 370.

Research output: Contribution to journalArticle

2 Scopus citations

Emerging uses of biomarkers in lung cancer management: Molecular mechanisms of resistance

Attarian, S., Rahman, N. & Halmos, B., Sep 1 2017, In : Annals of Translational Medicine. 5, 18, 377.

Research output: Contribution to journalArticle

8 Scopus citations

HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status

Cheng, H., Janakiram, M., Borczuk, A., Lin, J., Qiu, W., Liu, H., Chinai, J. M., Halmos, B., Perez-Soler, R. & Zang, X., Feb 1 2017, In : Clinical Cancer Research. 23, 3, p. 825-832 8 p.

Research output: Contribution to journalArticle

29 Scopus citations

Interaction of treatment and biomarker in advanced non-small cell lung cancer

Fu, P., Pennell, N. A., Sharma, N., Yi, Q., Dowlati, A. & Halmos, B., Mar 1 2017, In : Reviews on Recent Clinical Trials. 12, 1, p. 51-58 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

MET–GRB2 signaling-associated complexes correlate with oncogenic MET signaling and sensitivity to MET kinase inhibitors

Smith, M. A., Licata, T., Lakhani, A., Garcia, M. V., Schildhaus, H. U., Vuaroqueaux, V., Halmos, B., Borczuk, A. C., Chen, Y. A., Creelan, B. C., Boyle, T. A. & Haura, E. B., Nov 15 2017, In : Clinical Cancer Research. 23, 22, p. 7084-7096 13 p.

Research output: Contribution to journalArticle

8 Scopus citations

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

Schrock, A. B., Li, S. D., Frampton, G. M., Suh, J., Braun, E., Mehra, R., Buck, S. C., Bufill, J. A., Peled, N., Karim, N. A., Hsieh, K. C., Doria, M., Knost, J., Chen, R., Ou, S. H. I., Ross, J. S., Stephens, P. J., Fishkin, P., Miller, V. A., Ali, S. M. & 2 others, Halmos, B. & Liu, J. J., Jun 2017, In : Journal of Thoracic Oncology. 12, 6, p. 932-942 11 p.

Research output: Contribution to journalArticle

45 Scopus citations
2016

An analysis of the relationship between metastases and cachexia in lung cancer patients

Shiono, M., Huang, K., Downey, R. J., Consul, N., Villanueva, N., Beck, K., Fenn, K., Dietz, D., Yamaguchi, T., Kato, S., Divgi, C., Kalinsky, K., Wei, Y., Zhang, Y., Borczuk, A. C., Inoue, A., Halmos, B. & Acharyya, S., Sep 1 2016, In : Cancer Medicine. 5, 9, p. 2641-2648 8 p.

Research output: Contribution to journalArticle

11 Scopus citations

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

Cheng, H., Zhang, Z., Rodriguez-Barrueco, R. R., Borczuk, A., Liu, H., Yu, J., Silva, J. M., Cheng, S. K., Perez-Soler, R. & Halmos, B., May 17 2016, In : Oncotarget. 7, 20, p. 28976-28988 13 p.

Research output: Contribution to journalArticle

32 Scopus citations

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort

Goel, S., Hall, J., Pradhan, K., Hirsch, C., Przychodzen, B., Shastri, A., Mantzaris, I., Janakiram, M., Battini, R., Kornblum, N., Derman, O., Gritsman, K., Al-Hafidh, J., Wang, Y., Halmos, B., Steidl, U. G., Maciejewski, J. P., Braunschweig, I. & Verma, A. K., Apr 29 2016, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

12 Scopus citations

Marked differences in CNS activity among EGFR inhibitors: Case report and mini-review

Pareek, V., Welch, M., Ravera, E., Zampolin, R. L., Sequist, L. V. & Halmos, B., Nov 13 2016, In : Journal of Thoracic Oncology. 11, 11, p. e135-e139

Research output: Contribution to journalArticle

8 Scopus citations

New twists in the AXL(e) of tumor progression

Halmos, B. & Haura, E. B., Oct 4 2016, In : Science Signaling. 9, 448, fs14.

Research output: Contribution to journalArticle

6 Scopus citations

Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations

Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., Mansukhani, M., Koul, S., Halmos, B. & Borczuk, A. C., Mar 10 2016, In : Journal of Clinical Oncology. 34, 8, p. 794-802 9 p.

Research output: Contribution to journalArticle

143 Scopus citations

Recent advances in the management of pulmonary sarcomatoid carcinoma

Shum, E., Stuart, M., Borczuk, A., Wang, F., Cheng, H. & Halmos, B., Apr 2 2016, In : Expert Review of Respiratory Medicine. 10, 4, p. 407-416 10 p.

Research output: Contribution to journalArticle

9 Scopus citations

Sunitinib activates Axl signaling in renal cell cancer

Van Der Mijn, J. C., Broxterman, H. J., Knol, J. C., Piersma, S. R., De Haas, R. R., Dekker, H., Pham, T. V., Van Beusechem, V. W., Halmos, B., Mier, J. W., Jiménez, C. R. & Verheul, H. M. W., Jun 15 2016, In : International Journal of Cancer. 138, 12, p. 3002-3010 9 p.

Research output: Contribution to journalArticle

18 Scopus citations

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression

Yong, K. J., Basseres, D. S., Welner, R. S., Zhang, W. C., Yang, H., Yan, B., Alberich-Jorda, M., Zhang, J., De Figueiredo-Pontes, L. L., Battelli, C., Hetherington, C. J., Ye, M., Zhang, H., Maroni, G., O'Brien, K., Magli, M. C., Borczuk, A. C., Varticovski, L., Kocher, O., Zhang, P. & 12 others, Moon, Y. C., Sydorenko, N., Cao, L., Davis, T. W., Thakkar, B. M., Soo, R. A., Iwama, A., Lim, B., Halmos, B., Neuberg, D., Tenen, D. G. & Levantini, E., Aug 3 2016, In : Science Translational Medicine. 8, 350, p. 350ra104

Research output: Contribution to journalArticle

26 Scopus citations

Update in lung cancer 2015

Spira, A., Halmos, B. & Powell, C. A., Sep 15 2016, In : American Journal of Respiratory and Critical Care Medicine. 194, 6, p. 661-671 11 p.

Research output: Contribution to journalArticle

5 Scopus citations
2015

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Wang, T. J. C., Saad, S., Qureshi, Y. H., Jani, A., Nanda, T., Yaeh, A. M., Rozenblat, T., Sisti, M. B., Bruce, J. N., McKhann, G. M., Lesser, J., Halmos, B., Stoopler, M. B., Lassman, A. B., Cheng, S. K. & Isaacson, S. R., Jul 1 2015, In : Neuro-Oncology. 17, 7, p. 1022-1028 7 p.

Research output: Contribution to journalArticle

25 Scopus citations

Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer

Halmos, B., Pennell, N. A., Fu, P., Saad, S., Gadgeel, S., Otterson, G. A., Mekhail, T., Snell, M., Kuebler, J. P., Sharma, N. & Dowlati, A., Aug 25 2015, In : Oncologist. 20, 11, p. 1298-1303 6 p.

Research output: Contribution to journalArticle

19 Scopus citations

RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., Otto, G. & 5 others, Hawryluk, M., Stephens, P. J., Miller, V. A., Piperdi, B. & Perez-Soler, R., Dec 2015, In : Cancer discovery. 5, 12, p. 1262-1270 9 p.

Research output: Contribution to journalArticle

48 Scopus citations

Simpson's paradox - Aggregating and partitioning populations in health disparities of lung cancer patients

Fu, P., Panneerselvam, A., Clifford, B., Dowlati, A., Ma, P. C., Zeng, G., Halmos, B. & Leidner, R. S., Dec 1 2015, In : Statistical Methods in Medical Research. 24, 6, p. 937-948 12 p.

Research output: Contribution to journalArticle

2 Scopus citations

Update in lung cancer 2014

Spira, A., Halmos, B. & Powell, C. A., Aug 1 2015, In : American journal of respiratory and critical care medicine. 192, 3, p. 283-294 12 p.

Research output: Contribution to journalArticle

27 Scopus citations
2014

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer

Levy, B., Spira, A., Becker, D., Evans, T., Schnadig, I., Camidge, D. R., Bauman, J. E., Hausman, D., Walker, L., Nemunaitis, J., Rudin, C. M., Halmos, B. & Bowles, D. W., Jul 2014, In : Journal of Thoracic Oncology. 9, 7, p. 1031-1035 5 p.

Research output: Contribution to journalArticle

24 Scopus citations

AXL kinase as a novel target for cancer therapy

Wu, X., Liu, X., Koul, S., Lee, C. Y., Zhang, Z. & Halmos, B., Jan 1 2014, In : Oncotarget. 5, 20, p. 9546-9563 18 p.

Research output: Contribution to journalArticle

Open Access
103 Scopus citations

Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report

Seetharamu, N., Melamed, J., Miller, G., Rotterdam, H., Gonda, T., Villanueva, G. & Halmos, B., Dec 1 2014, In : Journal of Gastrointestinal Cancer. 45, p. 108-111 4 p.

Research output: Contribution to journalArticle

1 Scopus citations

Modulation of ErbB2 blockade in ErbB2-positive cancers: The role of ErbB2 mutations and PHLDA1

Li, G., Wang, X., Hibshoosh, H., Jin, C. & Halmos, B., Sep 19 2014, In : PloS one. 9, 9, e106349.

Research output: Contribution to journalArticle

17 Scopus citations

Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples

Heymann, J., Bulman, W., Maxfield, R., Powell, C., Halmos, B., Sonett, J., Beaubier, N., Crapanzano, J., Mansukhani, M. & Saqi, A., Jan 1 2014, In : CytoJournal. 11, 1, 12.

Research output: Contribution to journalArticle

21 Scopus citations

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

Sharma, N., Pennell, N., Nickolich, M., Halmos, B., Ma, P., Mekhail, T., Fu, P. & Dowlati, A., Apr 2014, In : Investigational New Drugs. 32, 2, p. 362-368 7 p.

Research output: Contribution to journalArticle

22 Scopus citations

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status

Dabir, S., Kluge, A., McColl, K., Liu, Y., Lam, M., Halmos, B., Wildey, G. & Dowlati, A., Mar 1 2014, In : International Journal of Cancer. 134, 5, p. 1045-1054 10 p.

Research output: Contribution to journalArticle

8 Scopus citations
6 Scopus citations
2013

A Phase i Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer

Halmos, B., Jia, Y., Bokar, J. A., Fu, P., Adelstein, D. J., Juergens, R., Rodal, M. B. & Dowlati, A., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1244-1250 7 p.

Research output: Contribution to journalArticle

6 Scopus citations